# A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

> **NCT06157892** · PHASE2 · RECRUITING · sponsor: **Seagen, a wholly owned subsidiary of Pfizer** · enrollment: 172 (estimated)

## Conditions studied

- Breast Neoplasms
- Gastroesophageal Junction Adenocarcinoma
- HER2 Low Breast Neoplasms
- HER2 Positive Breast Neoplasms
- Stomach Neoplasms
- Triple Negative Breast Neoplasms
- Metastatic Breast Cancer
- Metastatic Gastric Cancer
- Advanced Breast Cancer
- Advanced Gastric Cancer

## Interventions

- **DRUG:** disitamab vedotin
- **DRUG:** tucatinib

## Key facts

- **NCT ID:** NCT06157892
- **Lead sponsor:** Seagen, a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-20
- **Primary completion:** 2029-07-28
- **Final completion:** 2029-07-28
- **Target enrollment:** 172 (ESTIMATED)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06157892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06157892, "A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06157892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*